Stocks · News reference
Adicet Bio Announces Safety And Efficacy Data From Phase 1 Study Evaluating Prulacabtagene Leucel In Patients With Systemic Lupus Erythematosus With Or Without Lupus Nephritis; Prula-Cel Generally Well Tolerated With No CRS Greater Than Grade 2 And No IEC-HS Or ICANS
-At 12-months, 54% of evaluable patients achieved DORIS remission and 50% of patients achieved CRR--All patients discontinued immunosuppressants –- All but one patient tapered background steroids to ≤5 mg prednisone
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Adicet Bio Reports Third Quarter 2026 Financial Results and Business Updates
Adicet Bio announced its financial results for the third quarter of 2026, reporting a reduced net loss and providing updates on its clinical development programs.
8-K filing — Adicet Bio, Inc. (ACET)
Filed: 2026-11-05 AccNo: 0001720580-26-000065 Size: 378 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Adicet Bio, Inc. announced the grant of a non-qualified stock option to a new employee as an inducement award.
Adicet Bio to Participate in Upcoming Investor Conferences
Adicet Bio, Inc. announced that its management team will participate in two investor conferences scheduled for November 2026.
Wedbush Maintains Outperform on Adicet Bio, Raises Price Target to $28
Wedbush analyst Robert Driscoll maintains Adicet Bio (NASDAQ:ACET) with a Outperform and raises the price target from $25 to $28.